Exploring New Therapies for MS With Research on T-bet+ memory B Cells: Rajiv Jain, PhD
At the 2023 ACTRIMS, the post-doctoral associate in the department of clinical neurosciences at the University of Calgary, spoke on the impact of researching T-Bet+ memory B cells for new therapies in multiple sclerosis. [WATCH TIME: 5 minutes]
WATCH TIME: 5 minutes
“Once you have a population identified as behaving differently than all the other B cell populations and once we know a bit more about the mechanism of how they're working, we can then know how to design a variety of different therapies.”
Based on research from cells in
Jain, post-doctoral associate, department of clinical neurosciences, University of Calgary, sat down for an interview with NeurologyLive® at the forum to talk more about his process of his research on T-Bet+ memory B cells. In addition, he also shared his reactions to the findings from his study as well as his thoughts on how his type of research could play a key role in other aspects of MS that clinicians should be aware of. He also provided context on the importance of research in autoimmune encephalomyelitis for understanding MS and other related autoimmune disorders.
REFERENCES
1. Jain R, Mendes A, Zein S, et al. T-bet+ Memory B Cells Induce Disease Relapses in Experimental Autoimmune Encephalomyelitis. Presented at ACTRIMS Forum 2023; February 23-25; San Diego, California. Cutting Edge Developments 1.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.